VSTM vs MGNX vs RCUS vs FATE

For growth investors, Verastem, Inc.

(VSTM) is the stronger pick with 209. 1% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Verastem, Inc. (VSTM) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -6. 4%, compared to -97. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: RCUS returned +40. 0% versus MGNX's -85. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MacroGenics, Inc.

(MGNX) is the lower-risk stock at 1. 43β versus Arcus Biosciences, Inc. 's 2. 00β — meaning RCUS is approximately 40% more volatile than MGNX relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 192% for MacroGenics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Verastem, Inc.

(VSTM) is pulling ahead at 209. 1% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Fate Therapeutics, Inc. grew EPS 29. 9% year-over-year, compared to -10. 3% for MacroGenics, Inc.. Over a 3-year CAGR, VSTM leads at 128. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MacroGenics, Inc.

(MGNX) is the more profitable company, earning -49. 9% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps -49. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGNX leads at -48. 7% versus -22. 2% for FATE. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, MacroGenics, Inc.

(MGNX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Arcus Biosciences, Inc. (RCUS) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGNX: -85. 0%, RCUS: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VSTM is a small-cap high-growth stock; MGNX is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.